Current studentsExisting staffContact us
 

Diagnostic Value of Plasma Annexin A2 in Early-Stage High-Grade Serous Ovarian Cancer

Simple item page
dc.contributor.authorLokman, N.A.
dc.contributor.authorRicciardelli, C.
dc.contributor.authorStephens, A.N.
dc.contributor.authorJobling, T.W.
dc.contributor.authorHoffmann, P.
dc.contributor.authorOehler, M.K.
dc.date.issued2021
dc.description.abstract<jats:p>Ovarian cancer (OC) is commonly diagnosed at advanced stage when prognosis is poor. Consequently, there is an urgent clinical need to identify novel biomarkers for early detection to improve survival. We examined the diagnostic value of the calcium phospholipid binding protein annexin A2 (ANXA2), which plays an important role in OC metastasis. Annexin A2 plasma levels in patients with high grade serous OC (n = 105), benign ovarian lesions (n = 55) and healthy controls (n = 143) were measured by ELISA. Annexin A2 levels were found to be significantly increased in patients with stage I (p &lt; 0.0001) and stage IA (p = 0.0027) OC when compared to healthy controls. In the logistic regression models followed by receiver operating characteristics (ROC) curve analyses, plasma annexin A2 showed 46.7% sensitivity at 99.6% specificity in distinguishing stage IA OC patients from healthy controls and 75% sensitivity at 65.5% specificity in the diagnosis of stage IA versus benign ovarian tumors. In the diagnosis of stage IA OC versus normal controls, the combination of plasma annexin A2 and CA125 showed 80% sensitivity at 99.6% specificity (AUC = 0.970) which was significantly higher than for CA125 (53.3% sensitivity at 99.6% specificity; AUC = 0.891) alone. The diagnostic accuracy in distinguishing stage IA OC from benign ovarian disease when combining annexin A2 and CA125 (71.4% accuracy at 100% sensitivity) was almost twice as high compared to CA125 (37.1% accuracy at 100% sensitivity) alone. In conclusion, annexin A2 in combination with CA125 has potential as a biomarker for the early detection of OC and to predict malignancy in patients with ovarian lesions, warranting further investigations.</jats:p>
dc.identifier.citationDiagnostics, 2021; 11(1):1-10
dc.identifier.doi10.3390/diagnostics11010069
dc.identifier.issn2075-4418
dc.identifier.issn2075-4418
dc.identifier.orcidLokman, N.A. [0000-0002-2071-5308]
dc.identifier.orcidRicciardelli, C. [0000-0001-7415-1854]
dc.identifier.orcidHoffmann, P. [0000-0002-6573-983X]
dc.identifier.orcidOehler, M.K. [0000-0002-2651-5913]
dc.identifier.urihttps://hdl.handle.net/11541.2/147809
dc.language.isoen
dc.publisherMDPI AG
dc.relation.fundingOvarian Cancer Research Foundation (OCRF), Australia
dc.rightsCopyright 2021 1 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY4.0) license (https://creativecommons.org/licenses/by/4.0/)
dc.source.urihttps://doi.org/10.3390/diagnostics11010069
dc.subjectannexin A2
dc.subjectplasma
dc.subjectovarian cancer
dc.subjectCA125
dc.subjectearly detection
dc.subjectbiomarkers
dc.subjectHGSOC
dc.titleDiagnostic Value of Plasma Annexin A2 in Early-Stage High-Grade Serous Ovarian Cancer
dc.typeJournal article
pubs.publication-statusPublished
ror.fileinfo12228488200001831 13228498250001831 diagnostics-11-00069 (1).pdf
ror.mmsid9916536211401831

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
9916536211401831_12228488200001831_diagnostics-11-00069 (1).pdf
Size:
1.27 MB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections